Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action
JCO Oncology Practice · 2025
DOI: 10.1200/op-25-00827 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Canan D Dirican und 6 weiteren Autor:innen. Beteiligte Einrichtung: NYMC Internal Medicine Residency Program at Saint Mary's and Saint Clare's, Denville, NJ. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Hispanic or Latino, Black or African American. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Black men face the highest incidence and mortality rates of prostate cancer globally, including a disproportionate burden of metastatic castration-resistant prostate cancer (mCRPC). Despite this, clinical trials often fail to adequately represent the populations most affected. This study evaluates representation trends in mCRPC trials over a 17-year period. MATERIALS AND METHODS We analyzed 33 phase III and IV mCRPC trials (2005-2021) registered on ClinicalTrials.gov. Data on race, ethnicity, and trial geography were extracted. Representation trends were assessed across time intervals and funding sources. A random-effects model was used to analyze pooled participant demographics. RESULTS Of 33 trials (n = 28,746), 73% reported race and 42% reported ethnicity. Among trials with available data, 79.2% of participants were White, 10.8% were Asian, and only 3.8% were Black or African American. Hispanic participation was 6.7%. Notably, Black participation declined from 13.7% to 3% over the study period. Trial sites were predominantly located in North America and Europe, with no inclusion from Africa or the Caribbean. CONCLUSION Racial and ethnic under-representation in mCRPC trials has remained profound and, in some cases, worsened, despite increasing awareness. These findings underscore a critical need for structural reforms in trial design, funding, and regulatory oversight to ensure equitable access and generalizability of prostate cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- NYMC Internal Medicine Residency Program at Saint Mary's and Saint Clare's, Denville, NJ.
- Division of Hematology and Medical Oncology, Saint Michaels Medical Center, Newark, NJ.
- Division of Hematology and Medical Oncology, Saint Mary's General Hospital, Passaic, NJ.
ORCID-Profile: Canan D Dirican, Amara Sofia
Zitieren
APA
Dirican, C. D., Patel, S., Al Mardini, A., Sofia, A., Fernandes, B. A. C., Gondhi, V., & Maroules, M. (2025). Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action. JCO Oncology Practice. https://doi.org/10.1200/op-25-00827
Vancouver
Dirican CD, Patel S, Al Mardini A, Sofia A, Fernandes BAC, Gondhi V, et al. Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action. JCO Oncology Practice. 2025. doi:10.1200/op-25-00827
BibTeX
@article{Dirican2025,
author = {Dirican, Canan D and Patel, Sagar and Al Mardini, Anas and Sofia, Amara and Fernandes, Bolivia Aloysia Crocete and Gondhi, Venkatesh and Maroules, Michael},
title = {Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action},
journal = {JCO Oncology Practice},
year = {2025},
doi = {10.1200/op-25-00827}
}
EUVIMED